BRAF and metastatic melanoma: Notably, there are promising clinical trials underway that are investigating overcoming immunotherapy resistance, one being NCT05304546, a Phase 2 trial using pembrolizumab, encorafenib, or binimetinib to overcome primary resistance to immunotherapy (singular inhibitor or immune checkpoint blockade) in Stage IV or inoperable stage III metastatic melanoma patients with a BRAF V600 E/K mutation [113,114].